Cancer Drug Fails Test, and the Company’s Stock Tumbles
Telik, a biotechnology company, said Tuesday that a cancer treatment in the experimental stage failed to improve survival in patients with advanced lung cancer or in patients with ovarian cancer, setting off a 70 percent decline in its share price.
This entry was posted on Saturday, December 30th, 2006 at 12:39 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.